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Lymphokine-activated killer (LAK)' cells represent an operationally defined
lymphoid population that can lyse NK-resistant fresh tumor cells upon culture
in IL-2 (1, 2). The peripheral blood cell precursors (P) from which LAK cells
arise are mostly confined within a lymphoid subset expressing the CD 16 (Leu-
11, Fcy receptor) antigen, displaying large granular lymphocyte (LGL) mor-
phology and expressing NK activity (3-5). However, according to recent data
(6), at least some LAK cells and their precursors (LAK-P) belong to the T cell
lineage and give rise to cell clones with mature T cell phenotype (CD2+, CD3').
Regarding the LAK effector mechanism, little is known about the surface
molecules involved in cell-to-cell adhesion, target cell recognition, and lysis.
mAbs to LFA-1 molecule have recently been shown (7) to inhibit LAK activity.
However LFA-1 is a surface structure widely expressed on lymphoid and (some)
non lymphoid cell populationsand thus is involved in several cell functions. Here
we describe a novel 120-kD surface antigen, termed LAK-1, that is expressed by
virtually all LGL and includes the entire LAK-P pool. More importantly, unlike
other LGL/NK cell markers, this antigen is expressed on the LAK effector cells
as well. Finally, the LAK-1 molecule appears to be involved in LAK effector
function, as indicated by the inhibition of target cell lysis by a specific mAb.
Materials and Methods
Production of the Anti-LAK-1 mAb.
￿
6-wk-old male DBA/2 mice were immunized with
the SF16 LAK clone as previously described (8). The immunization schedule consistedof
three weekly intravenous injections of 10' SF16 cells. After 10 d, the mice received a
booster injectionof 1 .5 x 10 cellsfollowed by splenectomy 3 d later. Immune splenocytes
were fused with P3-U 1 myeloma cells (8). The initial screeningof hybridoma supernatants
(SN) was carried out usingan indirect RIA: 105 SF16 cells were incubated with 100 kl of
the various supernatants for 30 min in ice. "'I-labeled rabbit anti-mouse antibody was
then added for 1 h at 37 °C. Subsequently, the cells were harvested and counted using a
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,y-scintillation counter. The F(ab')2 fragment was derived by digestion with pepsine from
the purified mAb as described by Parham (9). The F(ab')2 piece appeared in SDS-PAGE
as an homogeneous band of ^-100 kD. Other mAbs used in these studies were: Leu 7
(anti HNK-1) and Leu 11 (anti-CD16) (purchasedfrom Becton Dickinson & Co, Sunnyvale,
CA) and the previously described (10) MAR 21 (anti-CD7) and J90 (anti-LFA-1) mAbs.
Isolation of Subpopulations of Peripheral Blood.
￿
Human PBMC and granulocytes were
isolated from healthy volunteer donors by Ficoll-Hypaque (F/H) density gradient centrif-
ugation. E+ and E- cell fractions were obtained by rosetting PBMC with neuraminidase-
treated sheep erythrocytes (11). The two fractions were separated by a F/H gradient
centrifugation. Monocytes were isolated by adherence on plastic Petri dishes. After
extensive washes to remove nonadherent cells, the adherent cells were detached by
incubation in ice for 2 h. B cell-enriched population was obtained by removing E-rosetting
cells from a spleen cell suspension. The residual population contained >95% of sIg+ cells.
Platelets were isolated after F/H density gradient centrifugation of heparinized blood.
LAK-1 + and LAK-1- cells were sorted with a FACS (FACS II ; Becton Dickinson Immu-
nocytometry Systems, Mountain View, CA) after indirect immunofluorescence staining
of PBMC with the LAK-1 mAb (12).
Indirect Immunofuorescence and Flow Cytofluorometric Analysis.
￿
Cells were stained with
hybridoma supernatants (25 I.1/105 cells) followed by fluoresceinated goat F(ab')2 anti-
mouse Ig as previously described (12). The samples were analyzed on a flow cytometer
gated to exclude nonviable cells. Results are expressed as arbitrarily normalized fluores-
cence histograms, i.e., number of cells vs. fluorescence intensity.
LAK Activation and Cytotoxicity Assay.
￿
PBMC at 106/ml concentration were cultured at
37 ° C for 3 d in complete medium (RPMI containing 20% FCS) supplemented with 50
U/ml of rIL-2 (Cetus Corp., Emeryville, CA). The cells were then harvested, washed
twice, and used as effector cells for lysis of cryopreserved fresh melanoma tumor cells.
Lysis was tested in a 4-h "Cr-release assay at the E/T ratio of 10:1 . The results are
expressed in percent specific lysis (13). In the inhibition experiments, effector cells were
preincubated with graded amounts (0.01-100,ug/ml) of either purified anti LAK-1 mAb
or of the F(ab')2 fragment of the same antibody, for 1 h at room temperature (RT),
washed twice, and used in the "Cr-release assay. As a control we used anti-CD7 or anti-
LFA-1 mAbs.
Characterization ofthe LAK-I Antigen.
￿
JA3 cells (8) were surface-labeled with '211 using
lactoperoxidase/glucose oxidase-catalyzed iodination (14). Cells were then washed five
times in cold RPMI 1640, twice in PBS, and lysed in 10 mM Tris-buffered saline (pH 7.5)
containing 1% NP-40, 1 mg/ml BSA, and 0.1 mM PMSF, for 20 min at 4°C. After
spinning at 100,000 g, the supernatant was then immunoprecipitated as follows. Super-
natants were dialyzed with PBS containing 0 .05% NP-40 and 0.1 mM PMSF and
precleared three times with 100 ul of packed protein A-Sepharose beads for 2 h under
rotation . Aliquots (200 ul) were then incubated for 2 h with 20 JAI of a 1 :10 dilution of
anti-LAK-1 mAb. 20 yl of packed protein A-Sepharose beads were then added and
samples were incubated for 4 h at 4°C. The immunoprecipitate was eluted from protein
A-Sepharose by boiling for 2 min in 5% SDS in the presence or absence of 5% 2-ME and
analyzed on 8% discontinuous SDS-polyacrylamide gels (15).
Results and Discussion
To produce mAbs directed against surface molecules expressed by human
LAK cells, DBA/2 mice were immunized with the clone SF16 derived as
previously described (13), which displays a strong cytolytic activity against a
variety of fresh or cultured human tumor cells (13). The surface phenotype of
the SF-16 clone as assessed by immunofluorescence and FACS analysis was CD3 -,
CD28- (Tp44), CD4-, CD8- , CD2+, CD7 +, HLA-DR', HNK-1 - . This clone,
which was derived from peripheral blood CD16+ cells, was weakly stained by
anti-CD 16 (Leu-11) mAb. After fusion, hybridoma SN were first screened forJ
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FIGURE I . Fluorescence distribution
of LAK-1 antigen on unfractionated
PBMC (A) E-rosetting-positive (B) and
A TJ
￿
B jq
￿
c E-rosetting-negative peripheral blood
cell fractions (C). The various cell pop-
ulations were stained with anti-LAK-1
mAb followed by fluoresceinated anti-
mouse Ig. The dotted lines indicate the
background fluorescence obtained using
FLUORESCENCE INTENSITY (AU)
￿
the second reagent alone. Samples were
run on a FACS II gated to exclude non-
viable cells.
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their ability to bind to SF-16 cells. Selected mAbs were further analyzed by
immunofluorescence for their reactivity with (a) unfractionated, E+ and E-
peripheral blood mononuclear cells; (b) normal B cell-enriched spleen cells; (c)
EBV-transformed B cell lines (including Raji, Daudi, BCLL, SKW6.9); (d) T cell
lines; (e) monocytes, granulocytes, and platelets. Anti-LAK-1 mAb, like anti-
CD 16 and anti-HNK-1 mAbs, reacted with some T cell lines, including HSB-2,
JA3, and Peer, whereas it did not react with either CEM or HPB-ALL T cell
lines, nor with any of the B cell lines or normal spleen B cells analyzed. ^-30%
monocytes were LAK-1', whereas platelets did not react with the mAb. FACS
analysis of isolated granulocytes showed that LAK-1 mAb was weakly reacting
with the majority of these cells. Fig. 1 shows the pattern of reactivity of anti-
LAK-I mAb with different PBMC populations. The surface antigen recognized
by anti-LAK-1 mAb displayed a clear bimodal distribution in all PBMC popula-
tions analyzed; thus, LAK-l' cells represented ^-50 and 15% of E- and E+ cell
fractions, respectively. In 10 different individuals, the percentage of LAK-l +
cells in unfractionated PBMC populations ranged between 15 and 30%. Given
the bimodal fluorescence distribution, LAK-l + and LAK-1 - cells could be sepa-
rated by FACS sorting and further analyzed for morphology and functional
capabilities. >90% of LAK-l + cells were LGL, as assessed by May-Grunwald
Giemsa and naphthol-AS-D chloroacetate esterase (NCAE) staining (not showN
(16). The remaining LAK-I+ cells (<10%) were represented by monocytes. The
LAK-1 - cell fraction was represented by small lymphocytes, monocytes, and
<2% LGL . As shown in Fig. 2, virtually all the NK activity exhibited by fresh
PBMC was confined to the LAK-l + fraction. In addition, when LAK-1 + and
LAK-1 - cells were cultured with rIL-2 and analyzed at different time intervals
for their ability to lyse fresh melanoma target cells (Fig. 2), LAK activity was
clearly confined to the LAK-l + population . The cytolytic activity of this popu-
lation was higher than that generated in unfractionated PBMC. Note also that
unlike PBMC, LAK-l + cells maintained a strong LAK activity for a relatively
long culture interval . These data indicate that the majority of the cells belonging
to the LAK precursor pool express the LAK-1 surface antigen. Furthermore,
>90% of the LAK-l + cells remained positive after 7 d of culture in rIL-2 (Fig.
3), whereas the LAK-1 - population did not express LAK-1 antigen after culture
under the same conditions (not shown).
We next investigated whether LAK-1 was expressed on the LAK cells con-
tained in unfractionated PBMC after culture in rIL-2. To this end, PBMC
populations that had been cultured for 3 d in rIL-2 were separated by FACS322
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FIGURE 2.
￿
Cytolytic activity of LAK-1' (0) and LAK-1- (A) cell populations fractionated
either before (A and B) or after (C and D) culture in rIL-2. The cytolytic activity of
unfractionated PBMC (/)is shown forcomparison. PBMC were sorted into LAK-1' and LAK-
1- cells and cultured in 50 U/ml rIL-2 (A and B). The cytolytic activity against the NK-
resistant fresh melanoma cellsand against the NK-sensitive K562 cell line was tested either 12
hafterseparation (day 0) or at days 3and 7.Experiments reported in CandDwere performed
after culturing unfractionated PBMC in 50 U/ml rIL-2 followed by sorting of LAK-1' and
LAK-1- populations. The two subsets, as well as the unfractionated populations, were recul-
tured in rIL-2and then assessed forcytolyticactivity either 12 h after separation (day 3) or at
day 7 and 14.
FIGURE 3.
￿
Stability of LAK-
1 antigen expression. The
expression of LAK-l, and
CD16 antigens was analyzed
on the purified LAK-l' pop-
ulation after different culture
intervals in rIL-2. Cells were
stained either with anti-LAK-
1 mAb (top panels) and the
fluoresceinated second re-
agent or with the fluorescein-
ated anti-CD16 (Leu-11) mAb
FLUORESCENCE INTENSITY (AU)
￿
(bottompanels)and analyzed at
the FACS. (Left panels) Fluorescence distribution of the different antigens on a purified LAK-1'
population 12 h after cell sorting. (Middle and right panels) Expression of the two antigens after 10
and 20 d of culture in AL-2 .
into LAK-1+ and LAK-1- subsets (FACS analysis showed a clear bimodal distri-
bution of LAK-I expression on these cells) and were analyzed for their cytolytic
activity against melanoma cells. Sorted cellswere extensivelywashed and cultured
for -12 h before performing the cytolytic assay. Fig. 2, C and D, show that
cytolytic cells were confined to the LAK-I' cell fraction . Taken together, these
data suggest that the expression of LAK-1 antigen represents a stable character-
istic of LAK cells. In another group of experiments, FACS-sorted peripheral
blood LAK-1+ cells were cultured for up to 3 wk in rIL-2 and analyzed at
differentculture intervals for the expression of LAK-1 antigen and other surface
antigens expressed by LGL, such as CD16 and HNK-1. Whereas the expression
of CD 16 (Fig. 3) and HNK-1 (not shown) decreased progressively during culture,
LAK-1 antigen was still brightly expressed on the majority of cells even after 20
d of culture (Fig. 3).
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TABLE I
Inhibition ofLAK Activity by anti-LAK-1 mAb Compared with
Anti-LFA-1 and anti-CD7 mAbs
PBMC were cultured for 3-5 d in HL-2, then incubated with the various mAbs for
I h at room temperature and used as effector cells in a "Cr-release assay against
fresh melanoma tumor cells (E/T ratio 10:1).
I
￿
I
￿
I
￿
I
10 1 0.1 0.01
Itg / ml
FIGURE 4.
￿
Inhibition of LAK activity mediated
by either purified anti-LAK-1 mAb (O) or the
F(ab')2 fragment (0). Results are expressed as per-
cent inhibition of LAK activity. LAK effector cells
were obtained by culturing PBMC for 3-5 d in
AL-2. LAK cells were then incubated with the
mAb for 1 h at room temperature and used as
effector cells in a "Cr-release assay against fresh
melanoma tumor cells (E/T ratio 10:1). The spe-
cific lysis of the target by LAK cells in the absence
of the mAb was -50%.
In another series of experiments we studied whether LAK-I was involved in
the cytolytic activity of LAK effector cells. As shown in Table 1, the LAK activity
ofPBMC cultured for 3 d in rIL-2 was inhibited by preincubation ofthe effector
cells with anti-LAK-1 or anti-LFA-1 mAb. On the other hand, an mAb directed
to the CD7 antigen (which is expressed also by all LAK cell clones studied so far)
(12) had noinhibitory activity. Similarly, LAK activity was not inhibited by mAbs
directed to HNK-I or CD16 antigens (data not shown). Unlike anti-LFA-I mAb,
however, anti-LAK-1 mAb did not inhibit the cytolytic activity ofalloreactive T
cell populations derived from mixed lymphocyte cultures (data not shown) . To
determine the concentration of anti-LAK-1 mAb needed for inhibition of lysis
offresh tumor targets, graded amounts either ofpurified mAb or ofthe F(ab')2
fragmentwere used inthe inhibition assay. As shownin Fig. 4, maximal inhibition
was observed with 10 ug/ml ofboth inhibitors.
Given the inhibitory activity of anti-LAK-1 mAb on LAK effector function,
we next investigated whether the mAb also inhibited the NK activity. Anti-LAK-
I mAb did not significantly block lysis of the NK-sensitive K562 target cells
either by freshly derived PBMC or by lymphocytes cultured for 3 d in rIL-2
(<20% inhibition). It is noteworthy, however, that in parallel experiments, anti-
LFA-1 mAb was also in most instances unable to efficiently block lysis of K562
target cells (not shown).
Exp.
None
Percent specific lysis
Anti-LFA-1
with mAbs
Anti-CD7
added
Anti-LAK-1
1 58 16 49 15
2 62 24 58 36
3 68 35 73 35
4 60 40 55 42
5 57 27 58 25
6 70 25 66 39324
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FIGURE
5
.
￿
Analysis
of LAK-I molecule by SDS-PAGE under
reducing
(b) or nonreducing (c) conditions
.
LFA-1 molecule (a)
is
shown for comparison
.
JA3 cells were surface-labeled with 1151
and
lysed as described in Materials and Methods
.
Cell lysates
were
immunoprecipitated with either one of the two mAbs and
protein
A-Sepharose
.
SDS-PAGE was performed in an 8%
polyacrylamide
gel followed by autoradiography
.
To
investigate the molecular nature of the surface antigen recognized by anti-
LAK-1
mAb, cells were labeled with "'I and the immunoprecipitated molecules
were
analyzed in SDS-PAGE
.
As shown in Fig
.
5, under both reducing and
nonreducing
conditions, LAK-1 precipitated as a band of ^
"120
kD
.
The mole-
cules
immunoprecipitated from the same labeled cells by an anti-LFA-1 mAb are
shown
for comparison
.
Taken
together, our data indicate that LAK-1 is a novel surface marker that
is
expressed on human LGLand includes LAK precursor cells
.
More importantly,
unlike
other LGL/NK cell markers, LAK-1 displays a noticeable stability of
expression
since effector cells with LAK activity were found to be LAK-1+ as
well
and the expression of LAK-1 was maintained for >3 wk of culture in rIL-2
.
The
fact that in resting PBMC the precursors ofLAK cells were LAK-1+ indicates
that
the expression of this antigen is not induced by rIL-2 during the process of
LAK
cell induction
.
The LAK-1 molecule is clearly distinct from other LGL/NK-
specific
antigens
.
Thus, CD 16, OKM1, NKH1, and NKH2 have different mo-
lecular
weights (17-19)
.
HNK-1 is expressed by only a fraction of LGL, more-
over,
the SF-16 immunizing clone was HNK-1-
.
In addition, the surface expres-
sion
of at least some of the above NK cell markers often decreases after cell
activation
(HNK-1, OKMI, and CD16) or culture in rIL-2
.
Thus, on the basis
of
LAK-1 expression it is now possible to isolate in PBMC a cell population
containing
LAK precursors
.
Moreover, it is also possible to isolate LAK effector
cells
from PBMC after culture in HL-2
.
An interesting property of LAK-1
molecule
is its involvement in LAK effector function
.
Thus, mAb to LAK-1
molecule,
similar to anti-LFA-1 antibody (13), inhibited lysis of fresh tumor
target
cells, but, unlike anti-LFA-1 mAb, did not inhibit alloreactive CTL
.
Both
mAbs
were shown to reduce LAK activity when added to the effector (but not
to
the target) cells
;
moreover, the tumor target cells were found to be negative
for
both LFA-1 and LAK-1 antigens (not shown)
.
Although both LFA-1 and
LAK-1
are involved in LAK function, the two molecules are clearly distinct with
respect
to their molecular structure
.
Moreover, unlike LFA-1, LAK-1 appears
to
be restricted to a functionally and phenotypically defined lymphocyte subset
.
The
finding that a minor proportion of T lymphocytes were LAK-1+ is not
surprising
since T cells contribute to the LAK-P pool and may display an LGL
morphology
(6)
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Summary
A human cell clone (SF-16) displaying strong cytolytic activity against fresh
tumor target cells was used for production of murine mAbs against surface
antigens expressed by lymphokine-activated killer (LAK) cells and their periph-
eral blood precursors. The preliminary screening of hybridoma supernatants
was performed according to the ability to bind SF-16 cells. Selected mAbs were
further analyzed for their reactivity with several T and B cell lines and with
peripheral blood T and non-T cell populations. A selected mAb, termed anti-
LAK-1, only reacted with some T cell lines and with 15-30% of PBMC. -10-
15% E-rosetting (T) cells and 40-50% E-rosette-negative cells were LAK-1*, as
determined by cytofluorometric analysis. As the fluorescence distribution of
LAK-1 antigen was clearly bimodal, LAK-1 + and LAK-1 - cells could be separated
by FACS. Positive cells were composed of large granular lymphocytes (LGL),
whereas negative cells were mostly small lymphocytes and monocytes without
LGL. After culture in rIL-2, purified LAK-1 + (but not LAK-1 -) cells acquired
the ability to lyse NK-resistant fresh melanoma target cells. In addition, only the
LAK-1+ fraction of PBMC cultured for 5 d in rIL-2 lysed fresh tumor targets,
thus indicating that the LAK-1 antigen is expressed also on LAK effector cells.
Unlike some other LGL/NK cell markers, LAK-1 antigen is characterized by a
stable expression : thus, LAK-1 + cell populations cultured for up to 20 d in rIL-
2 maintained the LAK-1 antigen expression, whereas HNK-1 and, partially,
CD16 were lost. Finally the cytolytic activity of LAK effector cells generated
from PBMC cultured for 3 d in rIL-2 was susceptible to inhibition by the anti-
LAK-1 mAb.
Receivedfor publication 29 january 1987 and in revisedform 27 April 1987.
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